Comparing the current results to its competitors, Tandem Diabetes Care Inc reported Revenue increase in the 1 quarter 2026 by 5.28 % year on year. The revenue growth was below Tandem Diabetes Care Inc 's competitors' average revenue growth of 9.07 %, achieved in the same quarter.
Tandem Diabetes Care Inc , slower than the average decrease reported by the company's competitors of -1.68 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -1.68 %
January 7, 2025
In a significant move to enhance diabetes management technologies, Tandem Diabetes Care, Inc. has entered a multi-year research collaboration with the University of Virginia Center for Diabetes Technology. The partnership aims to leverage UVA s pioneering advancements in closed-loop insulin delivery systems, which could revolutionize care for individuals living with diabetes.Tandem Diabetes Care, headquartered in San Diego and publicly traded on the Nasdaq under the symbol TNDM, focuses on developing technologies that improve insulin delivery. The new collaboration is poised to accelerate the development of fully automated insulin delivery systems often referred to as artificial pancreas technology that regu...
August 20, 2024
San Diego Tandem Diabetes Care, Inc. has announced the release of an updated version of its Apple iOS t:connect mobile app, designed specifically for users of the t:slim X2 insulin pump. Scheduled to be available on August 20, 2024, the app update, version 2.8.2, aims to correct battery depletion issues that were highlighted in a nationwide recall issued in March 2024. Users of the t:slim X2 insulin pump have reported experiencing unexpected battery drain, which can lead to the device shutting down before the expected time. This technical issue has persisted for some customers even after the prior update to version 2.7.1. The upcoming version 2.8.2 is anticipated to resolve these concerns and enhance the ...
August 10, 2024
In a significant development for investors in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), Bragar Eagel and Squire, P.C., a prominent shareholder rights law firm, has announced that it is investigating potential claims against the company on behalf of long-term stockholders. This scrutiny comes on the heels of a class action complaint lodged against Tandem, dated September 8, 2023, which pertains to a class period extending from August 3, 2022, to November 2, 2022.The core of the investigation revolves around allegations that the board of directors may have breached their fiduciary duties to the company and its shareholders during the specified period. Such breaches, if proven, could suggest that the company s...
January 8, 2024
In a groundbreaking collaboration, Tandem Diabetes Care, Inc., and Abbott have joined forces to integrate their cutting-edge technologies, marking significant advancements in insulin delivery and continuous glucose monitoring for individuals with diabetes. The recent integration of Tandem s t:slim X2 insulin pump with Control-IQ technology and Abbott s latest continuous glucose monitoring (CGM) system, the FreeStyle Libre 2 Plus sensor, has revolutionized the automated insulin delivery (AID) landscape.The integration of the t:slim X2 insulin pump with Control-IQ technology with Abbott s FreeStyle Libre 2 Plus sensor has ushered in a new era of convenience and accuracy in diabetes management. By combining the...
Dexcom Incs business model focuses on developing and selling continuous glucose monitoring systems for diabetes management. Their products provide real-time glucose level tracking, enabling users to better manage their condition through data-driven insights.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Modular Medical Inc operates with a business model focused on designing and manufacturing modular medical units, offering cost-effective and customizable solutions for healthcare providers looking to expand their facilities rapidly and efficiently. They aim to deliver innovative and turnkey solutions that can be easily deployed and scaled to meet the specific needs of their clients.
Myomo Inc's business model revolves around the development and commercialization of advanced medical devices, specifically myoelectric orthotics for individuals with neuromuscular disorders.
Insulet Corporation operates under a business model where they design, develop, and market innovative tubeless insulin delivery systems for people with diabetes. Their main product, the Omnipod System, is a wearable device that provides continuous insulin delivery without the need for traditional insulin pumps and tubing. This unique business model focuses on improving the quality of life for individuals with diabetes by offering a convenient and user-friendly insulin management solution.
Sources:
Tandem Diabetes Care Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tandem Diabetes Care Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
